Midlife systemic inflammatory markers are associated with late-life brain volume: The ARIC study

Neurology

Volumn 89, Issue 22, 2017, Pages 2262-2270

  Walker, Keenan A ^a   Hoogeveen, Ron C ^b,c   Folsom, Aaron R ^d   Ballantyne, Christie M ^b,c   Knopman, David S ^e   Windham, B Gwen ^f   Jack, Clifford R ^e   Gottesman, Rebecca F ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BLOOD CLOTTING FACTOR 8; FIBRINOGEN; VON WILLEBRAND FACTOR;

ADULT; AFRICAN AMERICAN; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; BRAIN SIZE; BRAIN VENTRICLE; CONTROLLED STUDY; EPISODIC MEMORY; FEMALE; GROWTH, DEVELOPMENT AND AGING; HIPPOCAMPUS; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDLIFE STAGE; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL LOBE; PRIORITY JOURNAL; RACE; AGE; ATHEROSCLEROSIS; BLOOD; BRAIN; CAUCASIAN; CLINICAL TRIAL; DEGENERATIVE DISEASE; DEMOGRAPHY; DIAGNOSTIC IMAGING; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE;

AFRICAN AMERICANS; AGE FACTORS; AGED; ATHEROSCLEROSIS; BRAIN; EUROPEAN CONTINENTAL ANCESTRY GROUP; FACTOR VIII; FEMALE; FIBRINOGEN; HUMANS; INFLAMMATION; LEUKOCYTE COUNT; MAGNETIC RESONANCE IMAGING; MALE; MEMORY, EPISODIC; MIDDLE AGED; NEURODEGENERATIVE DISEASES; PROSPECTIVE STUDIES; RESIDENCE CHARACTERISTICS; RISK FACTORS; SEX FACTORS; VON WILLEBRAND FACTOR;

EID: 85037998281     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000004688     Document Type: Article

References (39)

1. Tan ZS, Beiser AS, Vasan RS, et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham study. Neurology 2007;68:1902-1908.
2. DeKosky ST, Ikonomovic MD, Wang X, et al. Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment. Ann Neurol 2003;53:81-90.
3. Minett T, Classey J, Matthews FE, et al. Microglial immunophenotype in dementia with Alzheimer's pathology. J Neuroinflammation 2016;13:135.
4. Zhang H, Sachdev PS, Wen W, et al. The relationship between inflammatory markers and voxel-based gray matter volumes in nondemented older adults. Neurobiol Aging 2016;37:138-146.
5. Jefferson AL, Massaro JM, Wolf PA, et al. Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study 43. Neurology 2007;68:1032-1038.
6. Wersching H, Duning T, Lohmann H, et al. Serum Creactive protein is linked to cerebral microstructural integrity and cognitive function. Neurology 2010;74:1022-1029.
7. Bettcher BM, Wilheim R, Rigby T, et al. C-reactive protein is related to memory and medial temporal brain volume in older adults. Brain Behav Immun 2012;26:103-108.
8. Schmidt MF, Freeman KB, Windham BG, et al. Associations between serum inflammatory markers and hippocampal volume in a community sample. J Am Geriatr Soc 2016;64:1823-1829.
9. Satizabal CL, Zhu YC, Mazoyer B, Dufouil C, Tzourio C. Circulating IL-6 and CRP are associated with MRI findings in the elderly: the 3C-Dijon Study. Neurology 2012; 78:720-727.
10. Hill C, Gerardo D, James F, et al. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives: The ARIC Investigators. Am J Epidemiol 1989; 129:687-702.
11. Knopman DS, Griswold ME, Lirette ST, et al. Vascular imaging abnormalities and cognition: mediation by cortical volume in nondemented individuals: Atherosclerosis Risk in Communities: neurocognitive study. Stroke 2015;46:433-440.
12. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340:448-454.
13. Papp AC, Hatzakis H, Bracey A, Wu KK. ARIC hemostasis study: I: development of a blood collection and processing system suitable for multicenter hemostatic studies. Thromb Haemost 1989;61:15-19.
14. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997;96: 1102-1108.
15. Chambless LE, McMahon R, Wu K, Folsom A, Finch A, Shen YL. Short-term intraindividual variability in hemostasis factors: The ARIC study: Atherosclerosis Risk in Communities intraindividual variability study. Ann Epidemiol 1992;2:723-733.
16. Eckfeldt JH, Chambless LE, Shen YL. Short-term, withinperson variability in clinical chemistry test results: experience from the Atherosclerosis Risk in Communities Study. Arch Pathol Lab Med 1994;118:496-500.
17. Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002;33:341-355.
18. Dickerson BC, Stoub TR, Shah RC, et al. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology 2011;76:1395-1402.
19. Schneider ALC, Sharrett AR, Gottesman RF, et al. Normative data for 8 Neuropsychological tests in older blacks and whites from the Atherosclerosis Risk in Communities (ARIC) study. Alzheimer Dis Assoc Disord 2015;29:32-44.
20. Knopman DS, Gottesman RF, Sharrett AR, et al. Mild cognitive impairment and dementia prevalence: the Atherosclerosis Risk in Communities neurocognitive study: Alzheimer's dementia diagnosis. Assess Dis Monit 2016; 2:1-11.
21. Nägele U, Hägele EO, Sauer G, et al. Reagent for the enzymatic determination of serum total triglycerides with improved lipolytic efficiency. Clin Chem Lab Med 1984; 22:165-174.
22. Siedel J, Hagele EO, Ziegenhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 1983;29:1075-1080.
23. McNamara JR, Cohn JS, Wilson PWF, Schaefer EJ. Calculated values for low-density lipoprotein cholesterol in the assessment of lipid abnormalities and coronary disease risk. Clin Chem 1990;36:36-42.
24. Chetelat G, Baron JC. Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging. Neuroimage 2003;18:525-541.
25. Gottesman RF, Schneider ALC, Albert M, et al. Midlife hypertension and 20-year cognitive change. JAMA Neurol 2014;71:1218-1227.
26. Kivipelto M, Helkala EL, Hänninen T, et al. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology 2001;56:1683-1689.
27. Rawlings AM, Sharrett AR, Schneider ALC, et al. Diabetes in midlife and cognitive change over 20 years: a cohort study. Ann Intern Med 2014;161:785-793.
28. Krstic D, Knuesel I. Deciphering the mechanism underlying late-onset Alzheimer disease. Nat Rev Neurol 2013; 9:25-34.
29. Mensah GA, Mokdad AH, Ford ES, Greenlund KJ, Croft JB. State of disparities in cardiovascular health in the United States. Circulation 2005;111:1233-1241.
30. Green RC, Cupples LA, Go R, et al. Risk of dementia among white and African American relatives of patients with Alzheimer disease. J Am Med Assoc 2002;287:329-336.
31. Jurgens HA, Johnson RW. Dysregulated neuronalmicroglial cross-talk during aging, stress and inflammation. Exp Neurol 2012;233:40-48.
32. Lacroix S, Feinstein D, Rivest S. The bacterial endotoxin lipopolysaccharide has the ability to target the brain in upregulating its membrane CD14 receptor within specific cellular populations. Brain Pathol 1998;8:625-640.
33. Johnston GR, Webster NR. Cytokines and the immunomodulatory function of the vagus nerve. Br J Anaesth 2009;102:453-462.
34. Baune BT, Konrad C, Grotegerd D, et al. Tumor necrosis factor gene variation predicts hippocampus volume in healthy individuals. Biol Psychiatry 2012;72:655-662.
35. Cunningham C, Wilcockson DC, Campion S, Lunnon K, Perry VH. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J Neurosci 2005;25:9275-9284.
36. Sastre M, Walter J, Gentleman SSM, et al. Interactions between APP secretases and inflammatory mediators. J Neuroinflammation 2008;5:25.
37. Krstic D, Madhusudan A, Doehner J, et al. Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J Neuroinflammation 2012;9:151.
38. Gottesman RF, Rawlings AM, Sharrett AR, et al. Impact of differential attrition on the association of education with cognitive change over 20 years of follow-up. Am J Epidemiol 2014;179:956-966.
39. Hedman AM, van Haren NEM, Schnack HG, Kahn RS, Hulshoff Pol HE. Human brain changes across the life span: a review of 56 longitudinal magnetic resonance imaging studies. Hum Brain Mapp 2012;33: 1987-2002.